Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis

European Journal of Neurology

Volumn 17, Issue 2, 2010, Pages 226-231

  Niebroj Dobosz, I ^a   Janik, P ^b   Sokolowska B ^a   Kwiecinski, H ^b  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Amyotrophic lateral sclerosis; Cellular death; Matrix metalloproteinases; Neurodegeneration; Neuroinflammation

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 74549186988     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2009.02775.x     Document Type: Article

References (38)

1. Johnson C, Sung HJ, Lessner SM, Fini ME, Galls ZS. Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: potential role in capillary branching. Circ Res 2004 94 : 262 268.
2. Forsyth PA, Wong H, Laing TD, et al. Gelatinase A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 1999 79 : 1828 1835.
3. Chambaut-Guerin AM, Herigault S, Rouet-Benzineb P, Rouher C, Lafuma C. Induction of matrix metalloproteinase MMP-9 (92-kDa gelatinase) by retinoic acid in human neuroblastoma SKNBE cells: relevance to neuronal differentiation. J Neurochem 2000 74 : 508 517.
4. Azeh I, Mäder M, Smirnov A, Beuche W, Nau R, Weber F. Experimental pneumococcal meningitis in rabbits: the increase of matrix metallopropteinase-9 in cerebrospinal fluid correlates with leukocyte invasion. Neurosci Lett 1998 256 : 127 130.
5. Khrestchatisky M, Jourquin I, Ogier C, et al. Matrix metalloproteinase and their inhibitors, modulators of neuro-immune interactions and of pathophysiological processes in the nervous system. J Soc Biol 2003 197 : 133 144.
6. Kanoh Y, Ohara T, Kanoh M, Akahoshi T. Serum matrix metalloproteinase-2 levels indicate blood-CSF barrier damage in patients with infectious meningitis. Inflammation 2008 31 : 99 104.
7. Yong VW, Forsyth PA, Bell R, Krekoski CA, Edwards DR. Matrix metalloproteinase and diseases of the CNS. Trends Neurosci 1998 21 : 75 80.
8. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001 2 : 1681 1689.
9. Lukes A, Mun-Bryce S, Lukes M, Rosenberg GA. Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Mol Neurobiol 1999 19 : 267 284.
10. Asahi M, Asahi K, Jung JC, del Yoppo GJ, Fini ME, Lo EH. Role of matrix metalloproteinase 9 after focal cerebral ischemia, effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 2000 20 : 1681 1689.
11. Lorenzl S, Albers DS, LeWitt PA, et al. Tissue inhibitors of matrix metalloproteinses are elevated in cerebrospinal fluid of neurodegenerative diseases. J Neurol Sci 2003 207 : 71 76.
12. Renaud S, Leppert D. Matrix metalloproteinases in neuromuscular diseases. Muscle Nerve 2007 36 : 1 13.
13. Rosenberg G. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 2009 8 : 205 216.
14. Beuche W, Yushchenko M, Mäder M, Maliszewska M, Felgenhauer K, Weber F. Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport 2000 11 : 3419 3422.
15. Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Disease. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000 1 : 293 299.
16. MacNaul KL, Chartrain N, Lark M, et al. Discordinate expression of stromelysin, collagenase, and tissue inhibitor metalloproteinase-1 in rheumatoid human synovial fibroblasts: synergistic effects of interleukin-1 and tumor necrosis factors-α on stromelysin expression. J Biol Chem 1990 265 : 17238 17245.
17. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991 5 : 2145 2154.
18. Ries C, Petrides PE. Cytokine regulation of matrix metalloproteinase activity and regulatory dysfunction in disease. Biol Chem 1995 376 : 345 355.
19. Nelson KK, Melendez JA. Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med 2004 37 : 768 784.
20. Gu Z, Kaul M, Yan B, et al. S-nitrosylation of matrix metalloproteinase: signaling pathway to neuronal cell death. Science 2002 297 : 1186 1190.
21. Kähäri VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999 31 : 34 45.
22. Lorenzl S, Narr S, Angele B, et al. The matrix metalloproteinases inhibitor Ro 26-2853 extends survival in transgenic ALS mice. Exp Neurol 2006 200 : 166 171.
23. Bonnema DD, Webb CS, Pennington WR, et al. Effects of age on plasma matrix metalloproteinase (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail 2007 13 : 530 540.
24. Schoser BG, Blottner D. Matrix metalloproteinases MMP-2, MMP-7 and MMP-9 in denervated human muscle. Neuroreport 1999 10 : 2795 2797.
25. La-Fleur M, Underwood JL, Rappolee DA, Werb Z. Basement membrane and repair of injury to peripheral nerve: defining a potential role for macrophages, matrix metalloproteinases, and tissue inhibitor of metalloproteinase-1. J Exp Med 1996 184 : 2311 2326.
26. Noble LJ, Donovan F, Igarashi T, Goussev S, Werb Z. Matrix metalloptoteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J Neurosci 2002 22 : 7526 7535.
27. Larsen PH, Wells JE, Stallcup WB, Opdenakker G, Yong VW. Matrix metalloporteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoghlycan. J Neurosci 2003 23 : 11127 11135.
28. Lim G, Backstrom JR, Cullen MJ. Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients. J Neurochem 1996 67 : 251 259.
29. Kiaei M, Kipiani K, Calingasan NY, et al. Matrix metalloproteinase-9 regulates TNF-alpha and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 2007 205 : 74 81.
30. Niebroj-Dobosz I, Dziewulska D, Kwieciński H. Oxidative damage to proteins in the spinal cord in amyotrophic lateral sclerosis (ALS). Folia Neuropathol 2004 42 : 151 156.
31. Iłżecka J, Stelmasiak Z, Dobosz B. Extracellular matrix metalloproteinase-9 (MMP-9) in cerebrospinal fluid in amyotrophic lateral sclerosis patients (in Polish). Neurol Neurochir Pol 2001 35 : 1035 1043.
32. Apostolski S, Nikolic J, Bugarski-Prokopljevic C, Miletic V, Pavlovic S, Filipovic S. Serum and CSF immunologiocal findings in ALS. Acta Neurol Scand 1991 83 : 96 98.
33. Leonardi A, Abbruzzese G, Arata L, Cocito L, Vische M. Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis. J Neurol 1984 231 : 75 78.
34. Domitrz I, Kendziorek A, Wiśniewska W, Niebroj-Dobosz I. Intrathecal synthesis of IgG in amyotrophic lateral sclerosis. Mater Med Pol 1998 31 : 44 46.
35. Demestre M, Parkin-Smith G, Petzold A, Pullen AH. The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis. J Neuroimmunol 2005 159 : 146 154. Pol 2001;35:1035-1043.
36. Kherif S, Dehaupas M, Lafuma C, Fardeau M, Alameddine HS. Matrix metalloproteinases MMP-2 and MMP-9 in denervated muscle and injured nerve. Neuropathol Appl Neurosci 1998 24 : 309 319.
37. Dewil M, Schurmans C, Starckx S, Opdenakker G, van den Bosch L, Robberecht W. Role of matrix metalloporoteinase-9 in a mouse model for amyotrophic lateral sclerosis. Neuroreport 2005 16 : 321 324. (Pubitemid 40434558)
38. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007 6 : 1045 1053.